Abstract OT1-04-01: Adjuvant ovarian suppression plus aromatase inhibitor or tamoxifen for hormone receptor-positive breast cancer in women younger than 35 (ASPAIT): A multicenter randomized clinical trial

Hormone Receptor ◽

Ovarian Suppression ◽

NSABP B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared with Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor—Positive Breast Cancer

Clinical Breast Cancer ◽

10.3816/cbc.2006.n.061 ◽

2006 ◽

Vol 7 (5) ◽

pp. 416-421 ◽

Cited By ~ 30

Author(s):

Eleftherios P. Mamounas ◽

Barry Lembersky ◽

Jong-Hyeon Jeong ◽

Walter Cronin ◽

Barbara Harkins ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Aromatase Inhibitor ◽

Hormonal Therapy ◽

Hormone Receptor ◽

Disease Free Survival ◽

Free Survival ◽

Disease Free ◽

Abstract P1-15-03: Prevention of letrozole–induced bone loss using risedronate in postmenopausal women with hormone receptor positive breast cancer: A multicenter randomized clinical trial

10.1158/1538-7445.sabcs15-p1-15-03 ◽

2016 ◽

Author(s):

T Kadoya ◽

N Masumoto ◽

H Shigematsu ◽

A Emi ◽

K Kajitani ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Bone Loss ◽

Postmenopausal Women ◽

Hormone Receptor ◽

BPI21-008: Patient Preferences and Treatment Adherence to Adjuvant Ovarian Suppression Among Premenopausal Women With Hormone Receptor Positive Breast Cancer

Journal of the National Comprehensive Cancer Network ◽

10.6004/jnccn.2020.7759 ◽

2021 ◽

Vol 19 (3.5) ◽

pp. BPI21-008

Author(s):

Jasmine Singh Sukumar ◽

Dionisia Quiroga ◽

Mahmoud Kassem ◽

Michael Grimm ◽

Namrata Vilas Shinde ◽

...

Keyword(s):

Breast Cancer ◽

Treatment Adherence ◽

Patient Preferences ◽

Hormone Receptor ◽

Premenopausal Women ◽

Ovarian Suppression ◽

Abstract PS13-01: Primary analysis of OVERSTEP: A multicenter, randomized clinical trial of capecitabine or endocrine therapy as a maintenance therapy after the 1st-line chemotherapy in hormone receptor positive and HER2-negative advanced/metastatic breast cancer

10.1158/1538-7445.sabcs20-ps13-01 ◽

2021 ◽

Author(s):

Jian Huang ◽

Xiying Shao ◽

Li Cai ◽

Yanxia Shi ◽

Zhanhong Chen ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Metastatic Breast Cancer ◽

Maintenance Therapy ◽

Hormone Receptor ◽

Metastatic Breast ◽

Primary Analysis ◽

Line Chemotherapy

Abstract P6-04-17: The androgen metabolite-dependent growth in hormone receptor positive breast cancer as a novel aromatase inhibitor-resistance mechanism

10.1158/0008-5472.sabcs12-p6-04-17 ◽

2012 ◽

Author(s):

T Hanamura ◽

T Niwa ◽

S Nishikawa ◽

H Konno ◽

T Ghono ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Resistance Mechanism ◽

Aromatase Inhibitor Resistance ◽

Dependent Growth ◽

Inhibitor Resistance ◽

Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism

Breast Cancer Research and Treatment ◽

10.1007/s10549-013-2595-x ◽

2013 ◽

Vol 139 (3) ◽

pp. 731-740 ◽

Cited By ~ 29

Author(s):

Toru Hanamura ◽

Toshifumi Niwa ◽

Sayo Nishikawa ◽

Hiromi Konno ◽

Tatsuyuki Gohno ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Resistance Mechanism ◽

Aromatase Inhibitor Resistance ◽

Dependent Growth ◽

Inhibitor Resistance ◽

Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.658 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 658-658 ◽

Cited By ~ 9

Author(s):

J. Cuzick ◽

A. Howell

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Adjuvant Treatment ◽

Hormone Receptor ◽

Optimal Timing ◽

Postmenopausal Hormone ◽

Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)

10.1158/1538-7445.sabcs20-gs3-00 ◽

2021 ◽

Author(s):

Kevin Kalinsky ◽

William E Barlow ◽

Funda Meric-Bernstam ◽

Julie R Gralow ◽

Kathy S Albain ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Recurrence Score ◽

Phase Iii ◽

Her2 Breast Cancer ◽

First Results

Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-008-0735-5 ◽

2008 ◽

Vol 63 (2) ◽

pp. 261-266 ◽

Cited By ~ 38

Author(s):

Jae Hong Seo ◽

Yeul Hong Kim ◽

Jun Suk Kim

Keyword(s):

Breast Cancer ◽

Postmenopausal Woman ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Meta Analysis ◽

Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial

Cancer ◽

10.1002/cncr.33318 ◽

2020 ◽

Author(s):

Jose P. Leone ◽

Bernard F. Cole ◽

Meredith M. Regan ◽

Beat Thürlimann ◽

Alan S. Coates ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Clinical Behavior ◽

Breast International Group ◽

International Group ◽

Group 1 ◽